A group of researchers recently aimed to investigate the prognosis of patients with NSCLC that lacked a spouse, family members, or friends to support them during cancer treatment.
People undergoing cancer treatment often rely on their spouse, partner, family members, or friends for support as they deal with symptoms and side effects. But does the support of loved ones affect treatment outcomes, and how do these outcomes differ for individuals without it?
A group of researchers recently aimed to investigate this topic. Their study was recently published in Cureus and explored the impact of kinlessness on survival in patients with advanced non-small cell lung cancer (NSCLC). The study, conducted by Takashi Nojiri, M.D., Ph.D., and others from Higashiosaka City Medical Center in Japan, aimed to investigate the prognosis of patients with NSCLC that lacked a spouse, family members, or friends to support them during cancer treatment.
The retrospective, single-center study included 144 patients with advanced NSCLC who visited the medical center between November 2018 and February 2023. Among the patients, 13 were identified as kinless, meaning they did not have any immediate family or friends to support them.
The results showed that kinless patients had a significantly shorter overall survival compared to patients with kin. Patients with kin had a median survival of 1.34 years (95% CI of 1.01-1.79 years), while kinless patients had a median survival of 0.53 years (95% CI 0.23-0.76 years).
While the study's findings are limited by its small number of kinless participants, the findings highlight the importance of social support in prognosis of patients undergoing treatment for advanced NSCLC. The study provides valuable insights into the role of family support in cancer treatment decisions and outcomes, particularly in patients facing advanced stages of the disease.
“One possible reason for the poor prognosis of kinless advanced lung cancer patients is that it is difficult to manage cancer-related symptoms and adverse events that emerge during the treatment of NSCLC without a supporter,” the authors wrote in their paper.
These findings are notable considering the fact that more adults are living alone today than in the past. Marriage rates have been declining for decades in many countries, including the United States.
Further research is needed to evaluate the clinical impact of kinlessness on the management of advanced NSCLC. By having an awareness of the impact of kinlessness on survival in patients with NSCLC, managed healthcare professionals can better address the unique needs of individuals who may lack traditional support systems.
Combining Avastin With Alecensa Shows Promise in Advanced ALK-Positive Lung Cancer
May 29th 2025A phase 2 trial found that adding bevacizumab to alectinib significantly delayed disease progression, protected against brain metastases, and improved quality of life in patients with advanced ALK-positive lung cancer.
Read More
ICI-Chemo Combo Delivers More Benefit Than Harm, Even for High-Risk NSCLC Patients, Study Finds
May 16th 2025Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the treatment of non-small cell lung cancer. But it is open question whether they should be combined with traditional chemotherapy.
Read More
Time Well Spent: Lung Cancer Trials Offer Improved Survival Without Added Burden
May 7th 2025Researchers are exploring the topic of "time toxicity" — how much time patients spend receiving care. This study is the first to directly compare time spent in care between clinical trial participants and routine care patients receiving the same treatments.
Read More